• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Biovica International

0.36 SEK

-1.11 %

Less than 1K followers

BIOVIC B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.11 %
-1.11 %
-1.39 %
-3.78 %
-3.78 %
-53.28 %
-93.96 %
-99.11 %
-96.53 %

Biovica International is a pharmaceutical company that focuses its research on cancer treatment. The company develops blood-based biomarker tests to monitor and evaluate cancer treatments. The tests analyze the risk of developing the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main focus is on the treatment of breast cancer. Biovica International was founded in 2008 and is headquartered in Uppsala.

Read more
Market cap
103.92M SEK
Turnover
229.63K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Biovica is a Swedish biotechnology company founded in 2009. It was listed on the stock exchange in 2017. Its main product is the DiviTum TKa test: https://divitum.com/, which is a biomarker test that monitors and predicts treatment response in breast cancer. They received FDA approval...
8/31/2025, 1:45 PM
by OSAKEURPO
5
Biovica Q1 Interim report May 2025 – July 2025 - Biovica International AB 11.9 julkaistu osavuosi Tappio pieneni pikkaisen, mutta ei vielä merkittävää parannusta. Lisää myyntiä vaaditaan, että paastään luvattuun 2026 loppuvuoden voitolliseen tulokseen. Mielenkiinnolla seurailen mit...
9/18/2025, 12:09 PM
by Waldeboy
2
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10.9.
2026

Interim report Q1'27

16.9.
2026

General meeting '26

17.12.
2026

Interim report Q2'27

Regulatory press release01.07.2026 klo 10.15

Biovica granted Japanese patent for immuno-oncology

Biovica International
Regulatory press release30.06.2026 klo 14.00

Correction: Biovica refocuses US commercial strategy and terminates agreement with Tempus AI

Biovica International
Regulatory press release30.06.2026 klo 13.40

Biovica refocuses US commercial strategy and terminates agreement with Tempus AI

Biovica International

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release30.06.2026 klo 09.00

Biovica International AB - Annual Report for the financial year 2025/2026 published

Biovica International
Press release23.06.2026 klo 10.45

Redeye: Biovica (Q4 Review): Near-Term Estimates Pruned, Long-Term Conviction Intact

Biovica International
Press release17.06.2026 klo 11.00

Redeye: Live Q – Biovica

Biovica International
Regulatory press release17.06.2026 klo 09.00

Year-End Report 2025-2026

Biovica International
Regulatory press release28.05.2026 klo 09.30

New phase III translational data show DiviTum® TKa captures treatment-specific biological response in metastatic breast cancer

Biovica International
Regulatory press release26.05.2026 klo 09.45

Biovica receives expanded work order from clinical-stage oncology company for next-generation CDK inhibitor program

Biovica International
Regulatory press release05.05.2026 klo 22.30

Biovica International AB announces change in executive management

Biovica International
Regulatory press release30.04.2026 klo 11.00

New ESMO data highlights TKa across multiple treatment settings

Biovica International
Regulatory press release16.04.2026 klo 09.00

Theis Kipling to Assume Role as CEO of Biovica on May 1, 2026

Biovica International
Regulatory press release07.04.2026 klo 09.30

Theis Kipling new CEO for Biovica

Biovica International
Press release23.03.2026 klo 16.32

Redeye: Biovica (Q3 Review): Execution key as revenue drivers emerge

Biovica International
Regulatory press release18.03.2026 klo 09.05

New AACR data expand evidence for TKa in immunotherapy-treated patients and CDK inhibitor dose optimization

Biovica International
Regulatory press release18.03.2026 klo 09.00

Biovica International AB - Q3 Interim report Nov 2025-Jan2026

Biovica International
Regulatory press release09.03.2026 klo 18.00

Nomination Committee for Biovica International AB for the 2026 Annual General Meeting

Biovica International
Regulatory press release05.03.2026 klo 16.30

Biovica Announces Planned CEO Succession; Anders Rylander to Step Down During 2026

Biovica International
Regulatory press release12.02.2026 klo 09.30

Newly published data reinforce robust prognostic associations for DiviTum® TKa in metastatic breast cancer

Biovica International
Regulatory press release27.01.2026 klo 09.30

Strong DiviTum TKa results published in JCO Precision Oncology

Biovica International